Sökresultat - "PD‐1"

Advancement of Techniques for Precise Visualization and Quantification of Tertiary Lymphoid Structure-Associated Immune Cells in Tissue Samples

Klein, Christophe^{Aff3, Aff4}, Devi-Marulkar, Priyanka^{Aff4, Aff5, Aff6, Aff7}, Dieu-Nosjean, Marie-Caroline^{Aff8, Aff9, Aff10}, Germain, Claire^{Aff4, Aff5, Aff6, Aff11}

Dieu-Nosjean, Marie-Caroline^Aff2, Walker, John M.^Aff1

The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation

Ren, Jianghao^Aff4, Liu, Ruijun^Aff4

Huang, Tao^Aff1, Yang, Jialiang^Aff2, Tian, Geng^Aff3

Immuntherapie gastrointestinaler Tumoren

Immunotherapy for gastrointestinal cancer

Wirth, Thomas^{Aff1, IDs00761025016908_cor1}

Combination of Photodynamic Therapy Photodynamic therapy (PDT) and Immune Checkpoint Blockade Immune checkpoint blockade

Kleinovink, Jan Willem^Aff7, Ossendorp, Ferry^Aff7

Broekgaarden, Mans^Aff2, Zhang, Hong^Aff3, Korbelik, Mladen^Aff4, Hamblin, Michael R.^Aff5, Heger, Michal^Aff6, Walker, John M.^Aff1

CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.

Park, Soo, Ellison, David, Weight, Ryan, Homsi, Jade, Rabinowits, Guilherme, Ruiz, Emily, Strasswimmer, John, Simmons, Josh, Panella, Timothy, Quek, Ruben, Pouliot, Jean-Francois, Khushalani, Nikhil

application/pdf

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives.

Bujnak, Alyssa, File, Brittany, Tewari, Krishnansu

application/pdf

Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets

Pan, Kelly, Vromans, A. Maria, Cheng, Liang, Grant-Kels, Jane M., Katz, Steven C., Hadfield, Matthew J.^{Aff5, IDs1191202501693z_cor1}

On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC

Szabados, Bernadett E.^{Aff1, Aff2, IDs40487025003346_cor1}, Guerrero-Ramos, Félix, Grande, Enrique, Grivas, Petros, Grünwald, Viktor, Miguel, Marta Carpintero, Hussain, Syed A., Kulkarni, Girish S., Wilson, Ana Lisa, Shore, Neal D.^{Aff9, Aff10}, Sridhar, Srikala S., Hoyt, Mary, Strumeier, Samantha, Sutton, Jennifer, Brinkmann, Julia, Teresi, Rosemary E., Todenhöfer, Tilman

CD28 Superfamily Costimulatory Molecules in Chronic Pain: Focus on Immunomodulation

Shi, Qinglu, Luo, Yujia, Xiang, Qiaomin^{Aff1, Aff2}, Kang, Xianhui^{Aff3, IDs12035025047463_cor1}, Feng, Zhiying^{Aff1, IDs12035025047463_cor2}

The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia

Sun, Kai, Shi, Zong-Yan, Wang, Ya-Zhe, Xie, Dai-Hong, Liu, Yan-Rong, Jiang, Qian, Jiang, Hao, Huang, Xiao-Jun, Qin, Ya-Zhen^{Aff1, IDs00277025064187_cor1}

miR-128-3p Reduces Proliferation and Immune Escape in Acute Myeloid Leukemia Through Targeted Regulation of ZEB1

Zhang, YanBin^Aff1, Ma, DanDong^Aff2, Zhang, XiaoJuan, Chen, WenKun, Wang, XueJiao, Sun, Rui, Li, KuiXing^{Aff1, IDs12010025052558_cor1}

A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)—based on real-world data analysis

Zhang, Shaolong, Chen, Chuanjian, Mo, Chunhao, Fan, Ning, Ning, Zhongyun, Wang, Zhiping, Ding, Hui^{Aff1, IDs11255025045672_cor1}

Prediction of PD-1 Expression and Outcomes of Combined Therapy in Hepatocellular Carcinoma: an MRI-Based Radiomics Approach

Gu, Jingxiao^{Aff1, Aff2}, Bao, Shanlei^Aff4, Han, Lu, Yu, Xiao, Jia, Zhongzheng^{Aff3, IDs10278024013817_cor1}, Huang, Chen^{Aff2, IDs10278024013817_cor2}

Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes

Hammerstad, Sara S.^{Aff1, Aff2}, Lee, Hanna J., Tomer, Yaron, Stefan-Lifshitz, Mihaela^{Aff3, IDs40618025026082_cor1}

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Moehler, Markus, Oh, Do-Youn, Kato, Ken, Arkenau, Tobias, Tabernero, Josep, Lee, Keun-Wook, Rha, Sun Young, Hirano, Hidekazu, Spigel, David, Yamaguchi, Kensei, Wyrwicz, Lucjan, Disel, Umut, Pazo-Cid, Roberto A., Fornaro, Lorenzo, Xu, Yaling, Sheng, Tao, Yang, Silu, Kadva, Alysha, Cruz-Correa, Marcia, Xu, Rui-Hua^{Aff20, IDs12325025031337_cor1}

First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

Xu, Jianming, Kato, Ken, Hubner, Richard, Park, Sook Ryun, Kojima, Takashi, Ishihara, Ryu, Wyrwicz, Lucjan, Van Cutsem, Eric, Jimenez-Fonseca, Paula, Wu, Hongqian, Wang, Lei, Yan, Sebastian, Shi, Jingwen, Kadva, Alysha, Yoon, Harry H.^{Aff14, IDs12325025031159_cor1}

Design and Production of a Novel Anti-PD-1 Nanobody by CDR Grafting and Site-Directed Mutagenesis Approach

Mirzaei, Mahsa, Mirhoseini, Shima, Heidari, Mohammad Mehdi^{Aff1, IDs12033024011621_cor1}, Khatami, Mehri

Fangchinoline-mediated autophagy inhibition amplifies antigen presentation and PD-1 blockade efficacy in lung cancer

Song, Yue^{Aff1, Aff2}, Jiang, Yu-xiao^Aff3, Guan, Jie-ying^Aff4, Jiang, Jun-bo, Xu, Man-si, Zhong, Xue-ying, He, Li-na, Ren, Zhen-yang, Liao, Yuan, Liu, Fang, Jiang, Yan-jun, Hu, Shan, Guo, Wei, Zhao, Ting-xiu, Liu, Xiao-yi, Gu, Jiang-yong, Shi, Ya-fei, Luo, Huan-huan^{Aff1, IDs41401025015417_cor1}, Wang, Kun^{Aff1, Aff4, IDs41401025015417_cor2}, Xiao, Jian-yong^{Aff3, IDs41401025015417_cor3}

Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study

Guo, Huili^{Aff1, Aff2}, Wu, Lili^{Aff1, Aff2}, Yu, Chengyou^{Aff1, Aff2}, Yu, Huiying^{Aff1, Aff2}, Deng, Wenjian, Zhao, Qiyi^{Aff1, Aff2}, Mo, Zhishuo^{Aff1, Aff2}, Lin, Bingliang^{Aff1, Aff2}, Gao, Zhiliang^{Aff1, Aff2, Aff3, IDs12072025108262_cor1}, Li, Xiaoyan^{Aff1, Aff2, IDs12072025108262_cor2}

Current clinical trials for craniopharyngiomas: what’s on the horizon?

Joshi, Nikhil, Mueller, Sabine^{Aff2, Aff3, IDs11060024048996_cor1}, Kline, Cassie